HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Toxicity of a Randomized Phase II Trial

被引：0
|
作者：
Jolicoeur, M. [1 ]
Derashodian, T. [1 ]
Nguyen-Huynh, T. [1 ]
Hillmann, E. de Castro [1 ]
Berbiche, D. [2 ]
Truchon, D. [1 ]
Heliou, R. [1 ]
Mondat, M. [1 ]
机构：
[1] Charles LeMoyne Hosp, Radiol Oncol, Greenfield Pk, PQ, Canada
[2] Charles LeMoyne Hosp, Ctr Rech, Greenfield Pk, PQ, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2021年 / 158卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-0121
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [31] 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer
    Kurek, R
    Shazikis, G
    Martin, T
    Baltas, D
    Anagnostopoulos, G
    Röddiger, SJ
    Sapoutzis, N
    Buhleier, T
    Dannenberg, T
    Tunn, UW
    Zamboglou, N
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 7 - 7
  • [32] What is the proper dose in single fraction HDR brachytherapy as monotherapy for prostate cancer?
    Ruiz Arrebola, S.
    Tornero-Lopez, A. M.
    De la Vega, J. M.
    Prada, P. J.
    Guirado, D.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S972 - S973
  • [33] HDR brachytherapy in monotherapy of one fraction in patients with prostate cancer at low risk
    Orduz Arenas, A. C.
    Jimenez Garcia, I.
    Martinez Gutierrez, R.
    Cucarella Beltran, P.
    Blanco Parajon, S.
    Gonzalez Suarez, H. A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S947 - S947
  • [34] HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis
    Viani, Gustavo Arruda
    Arruda, Caio Viani
    Assis Pellizzon, Antonio Cassio
    De Fendi, Ligia Issa
    [J]. BRACHYTHERAPY, 2021, 20 (02) : 307 - 314
  • [35] HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
    Moreno Olmedo, E.
    Nagore, G.
    Suarez-Gironzini, V.
    Minguez, C.
    Gomez, E.
    Garcia, A.
    Ciapa, V.
    Marrone, I.
    Lopez, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S123 - S123
  • [36] HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
    Moreno Olmedo, E.
    Nagore, G.
    Suarez Gironzini, V.
    Minguez, C.
    Gomez, E.
    Garcia, A.
    Ciapa, V.
    Marrone, I.
    Lopez, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1122 - S1123
  • [37] Adverse events after HDR brachytherapy as monotherapy in localized prostate cancer.
    Kariya, S.
    Kobayashi, K.
    Yamasaki, I.
    Ashida, S.
    Inoue, K.
    Yamagami, T.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1252 - S1253
  • [38] Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
    Vigneault, E.
    Morton, G.
    Perulekar, W.
    Niazi, T.
    Springer, G.
    Barkati, M.
    Chung, P.
    Koll, W.
    Kamran, A.
    Montreal, M.
    Ding, K.
    Loblaw, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S975 - S976
  • [39] HIGH-DOSE-RATE BRACHYTHERAPY AS A MONOTHERAPY FOR FAVORABLE-RISK PROSTATE CANCER: A PHASE II TRIAL
    Barkati, Maroie
    Williams, Scott G.
    Foroudi, Farshad
    Tai, Keen Hun
    Chander, Sarat
    van Dyk, Sylvia
    See, Andrew
    Duchesne, Gillian M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 1889 - 1896
  • [40] Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.
    D'alimonte, Laura
    Helou, Joelle Antoine
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Ravi, Ananth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345